Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.

Nicla La Verde, Anna Moretti, Gabriella Farina, Maria Chiara Dazzani, Teresa Gamucci, Karen Borgonovo, Mario Botta, Nello Salesi, Monica Zuradelli, Ida Pavese, Elena Barbieri, Elisabetta Cretella, Tiziana Saladino, Paola Varese, Elena Silvia Traverso, Gianfranco Addamo, Mariangela Ciccarese, Anna Iolanda Rispoli, Arianna Pellegrino, Lucia MentucciaSerena Girelli, Sheila Piva, Massimo Di Maio

Research output: Contribution to journalArticle

Abstract

This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.

Original languageEnglish
Pages (from-to)1841-1848
Number of pages8
JournalFuture Oncology
Volume9
Issue number12
Publication statusPublished - Dec 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.'. Together they form a unique fingerprint.

  • Cite this

    La Verde, N., Moretti, A., Farina, G., Dazzani, M. C., Gamucci, T., Borgonovo, K., Botta, M., Salesi, N., Zuradelli, M., Pavese, I., Barbieri, E., Cretella, E., Saladino, T., Varese, P., Traverso, E. S., Addamo, G., Ciccarese, M., Rispoli, A. I., Pellegrino, A., ... Di Maio, M. (2013). Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncology, 9(12), 1841-1848.